Clinical Trial Update: Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients [Phase 2]

View source ↗

Summary

Phase 2 study in HIV-positive adults assessed 48-week virologic and immunologic response to Kaletra (lopinavir/ritonavir). The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Kaletra (lopinavir)

Snippet

Sponsor: Therapeutic Concepts | Conditions: HIV Infections | Phase 2 | Status: COMPLETED